Stephen Huhn, MD

Dr. Huhn has over 15 years of biotech experience in early clinical development for a wide range of neuroscience indications and platforms. As CMO and SVP of Clinical Development for Pipeline Therapeutics, he is directing early clinical translation of a novel drug to restore hearing in SNHL associated with speech-in-noise impairment. Before coming to industry in 2007, Dr. Huhn was Chief of Pediatric Neurosurgery at the Lucile Packard Children’s Hospital at Stanford University and an Associate Professor in Neurological Surgery at Stanford University. He obtained his MD from the University of Arizona and completed neurosurgery training at the University of Maryland. Dr. Huhn also completed specialized fellowships in Neuro-Oncology at UCSF and Pediatric Neurosurgery at Northwestern University, and maintains board-certification in neurosurgery and as a Fellow in the American Association of Neurological Surgeons. He has served as an advisor and consultant in clinical development and strategy for multiple private and public biotech companies exploring innovative technologies in complex neurological disorders.